The discovery, published in Science Advances, centers on a gene called MYBBP1A. Studies suggest that as many as two-thirds of patient cases of the most common type of pancreatic tumor have the deletion of one copy of this gene in the tumor cells. Read more . . .
A DNA mutation that occurs frequently in the development of many pancreatic tumors appears to make these cancers vulnerable to an existing type of drug known as PARP inhibitors, according to a new study from scientists in the Perelman School of Medicine at the University of Pennsylvania.